Exploring options in Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) Type II

The ASTROSCAPE Study will explore whether a potential new treatment (also called an investigational drug) named radiprodil may help children and adolescents with drug-resistant seizures caused by Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II.

For many people with TSC or FCD Type II, current medications do not control their seizures (or stop controlling them over time).

This study is exploring whether investigational radiprodil can reduce seizures, and other symptoms, in children and adolescents whose seizures are not controlled by current approved medications.

The information on this website will help you understand more about the ASTROSCAPE Study. If you are an adolescent with TCD or FCD Type II, you may use this website to learn more about the ASTROSCAPE Study, but you will need your caregiver to request more details about joining.

If you have any questions, please contact your doctor.